BioCentury | Aug 13, 2007
Company News

Aegera, LymphoSign deal

...Aegera acquired LymphoSign for an undisclosed price. Aegera receives LymphoSign's LS104, a multiple tyrosine kinase inhibitor...
...Phase I/II trial to treat relapsed or refractory AML. Aegera Therapeutics Inc. , Montreal, Quebec LymphoSign Inc....
BioCentury | Jun 26, 2006
Company News

Tranzyme Pharma Inc. management update

...Hired: Helmut Thomas as SVP of research and preclinical development, formerly VP of R&D at LymphoSign Inc. WIR...
BioCentury | Mar 27, 2006
Clinical News

LymphoSign preclinical data

...28 days of treatment with the non-ATP competitive kinase inhibitor was safe and well tolerated. LymphoSign Inc....
Items per page:
1 - 3 of 3
BioCentury | Aug 13, 2007
Company News

Aegera, LymphoSign deal

...Aegera acquired LymphoSign for an undisclosed price. Aegera receives LymphoSign's LS104, a multiple tyrosine kinase inhibitor...
...Phase I/II trial to treat relapsed or refractory AML. Aegera Therapeutics Inc. , Montreal, Quebec LymphoSign Inc....
BioCentury | Jun 26, 2006
Company News

Tranzyme Pharma Inc. management update

...Hired: Helmut Thomas as SVP of research and preclinical development, formerly VP of R&D at LymphoSign Inc. WIR...
BioCentury | Mar 27, 2006
Clinical News

LymphoSign preclinical data

...28 days of treatment with the non-ATP competitive kinase inhibitor was safe and well tolerated. LymphoSign Inc....
Items per page:
1 - 3 of 3